N/A N=24 Randomized Double-blind Treatment

Effect of Artemisia Dracunculus on Glucose Intolerance, Insulin Sensitivity and Insulin Secretion

Glucose Intolerance

Bottom Line

View on ClinicalTrials.gov: NCT02330341 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Oct 2020

Primary outcome: Primary: Postprandial Glucose Levels at Week 12 — 9.5; 9.9 mmol/L — p=0.380

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Artemisia dracunculus (Dietary_supplement); Placebo (Other)
Age: Adult · 30+ yrs
Sex: All
Sponsor: University of Guadalajara
Primary completion: Jun 2015

Outcome Measures

Outcome	Result	p-value
PRIMARY Postprandial Glucose Levels at Week 12	9.5; 9.9	0.380
PRIMARY Fasting Glucose Levels at Week 12	5.9; 5.9	0.110
PRIMARY Glycosylated Hemoglobin at Week 12	5.6; 5.8	0.010 sig
PRIMARY First Phase of Insulin Secretion at Week 12	1235; 1566	0.733
PRIMARY Total Insulin Secretion at Week 12	0.35; 0.75	0.03 sig
PRIMARY Insulin Sensitivity at Week 12	2.4; 1.8	0.519
SECONDARY Weight at Week 12	85.3; 84.0	0.605
SECONDARY Body Mass Index at Week 12	33.2; 34.4	0.687
SECONDARY Total Cholesterol at Week 12	5.4; 5.0	0.339
SECONDARY Triglycerides Levels at Week 12	2.2; 1.8	0.775
SECONDARY High Density Lipoprotein (c-HDL) Levels at Week 12	1.4; 1.3	0.040 sig
SECONDARY Alanine Aminotransferase (ALT) Levels at Week 12	32.8; 36.7	0.021 sig
SECONDARY Aspartate Aminotransferase (AST) Levels at Week 12	30.3; 26.7	0.465
SECONDARY Creatinine Levels at Week 12	61.01; 61.01	0.480
SECONDARY Uric Acid Levels at Week 12	350.9; 309.3	0.034 sig
SECONDARY Systolic Blood Pressure at Week 12	113; 125	0.017 sig
SECONDARY Diastolic Blood Pressure at Week 12.	75; 79	0.170

Summary

The term prediabetes has been used to encompass the first alterations on glucose metabolism such as impaired fasting glucose and glucose intolerance, and its early detection and treatment could prevent the appearance of diabetes mellitus type 2, a high prevalence disease worldwide. Artemisia dracunculus, also known as estragon, has been used in Ayurvedic medicine for the treatment of diabetes. Different in vitro and in vivo studies have shown that Artemisia dracunculus increases insulin signaling and improves insulin sensitivity. The aim of this study is evaluate the effect of Artemisia dracunculus on glucose intolerance, insulin sensitivity and insulin secretion.

Eligibility Criteria

Inclusion Criteria

Patients both sexes
Age between 30 and 60 years
Glucose intolerance according ADA criteria (blood glucose leve ≥140 mg/dl and ≤199 mg/dL after an oral glucose tolerance test with 75 of oral glucose
Informed consent signed

Exclusion Criteria

Women with confirmed or suspected pregnancy
Women under lactation and/or puerperium
Hypersensibility to Artemisia dracunculus
Physical impossibility for taking pills
Known uncontrolled renal, hepatic, heart or thyroid disease
Previous treatment for glucose
Diabetes diagnosis
BMI ≥39.9 kg/m2

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02330341). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.